Prevention of the Angioenic Switch in Human Breast Cancer
Abstract
The overall goal of this research is to determine if human breast cancer can be prevented from becoming angiogenic when it is still at a microscopic size of less than approximately 1 mm(sub 3). We have made the following progress during the past year: (1) We have developed models in SCID mice of four different non-angiogenic human breast cancers, and have shown that the time to the switch to the angiogenic phenotype is predictable and reproducible for each different breast cancer type. The same is true for the percentage of tumors that become angiogenic. (2) Two angiogenesis-based biomarkers have been developed to detect the angiogenic switch when these tumors are still at a microscopic size of 1 mm(sub 3) or less. The most sensitive and accurate biomarker is the "platelet angiogenic profile," which determines and quantifies the angiogenic regulatory proteins being elaborated by a tumor. A second biomarker is a rise in circulating precursor endothelial cells exiting from the bone marrow and stimulated by a tumor that is undergoing the angiogenic switch. Our translational goal is to treat human breast cancer, both primary and recurrent, with non-toxic angiogenesis inhibitors guided by biomarkers before tumors can be anatomically located.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2005
- Accession Number
- ADA432781
Entities
People
- Judah Folkman